Pharmacists ready with Moderna boosters but services must be sustainable
Thursday 9th December 2021
The Pharmaceutical Society of Australia (PSA) welcomes the announcement that Moderna’s SPIKEVAX vaccine has been provisionally approved as a booster dose for Australians aged 18 years and above.
Yesterday, the Therapeutic Goods Administration (TGA) confirmed that a second vaccine will be available for the National Booster Program.
PSA National President, A/Prof Chris Freeman, acknowledged further enablement of the pharmacist workforce.
“With the National Booster Program well underway, this move is timely – one that provides Australians with greater vaccine choice in the lead up to early 2022 when the majority of the population becomes eligible for their booster dose.
“This announcement, coupled with Monday’s provisional approval of Pfizer for Australians aged 5-11 years, marks a week of significant progress in the pandemic response and PSA commends the Government’s approach to making these decisions.
“This development now means that the potential number of pharmacists offering booster vaccinations across Australia has more than doubled, accounting for those already participating in the Moderna program.
“However, it is imperative that pharmacists are paid fairly, and at least equally to other providers, otherwise the provision of this critical service is not sustainable. With 2.3 million children becoming eligible for vaccination, extra consultation time will be required to undertake appropriate assessment and consenting, placing further strain on service sustainability.
“Pharmacists have already administered over 2.5 million vaccinations to Australians, and as mass vaccination hubs continue to downscale their operations over the coming months, pharmacists will become an even more critical part of the vaccination strategy,” he said.
PSA is dedicated to supporting Australian pharmacist immunisers through the National Booster Program and will continue to work closely with the TGA and ATAGI to ensure pharmacists are equipped with the most up-to-date advice regarding vaccine safety and effectiveness.
Media contact: PSA media 0424 777 463